NCT01310413已完成3 期
Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 842
- 试验地点
- 18
- 主要终点
- Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain.
研究概览
简要总结
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to < 18 years of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or female child >= 6 months and < 18 years of age at the time of first vaccination.
- •Written informed consent obtained from the subject's parent/guardian.
- •Documentation of assent for children 9 to < 18 years of age (or as deemed mandatory by local practice).
- •Satisfactory baseline medical assessment by history and physical examination
- •Parent/guardian and subject access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.
- •Parents/guardians and subjects who the investigator believes understand the requirements of the protocol and can and will comply with them.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Female subjects of childbearing potential must
- •have practiced adequate contraception for 30 days prior to vaccination, and
- •have a negative pregnancy test on the day of each vaccination, and
- •have agreed to continue adequate contraception for 2 months after completion of the vaccination series.
排除标准
- •Medical history of physician-confirmed infection with an H5N1 virus.
- •Previous vaccination at any time with an H5N1 vaccine.
- •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/product, or planned use during the study period.
- •Presence of significant acute or chronic, uncontrolled medical or psychiatric illness.
- •Presence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject or parent/guardian unable/unlikely to provide accurate safety reports.
- •Evidence of current subject or parent/guardian substance abuse, including alcohol, by medical history.
- •Presence of a temperature >= 38.0ºC by any method, or acute symptoms greater than "mild" severity on the scheduled date of first dose.
- •Diagnosed with cancer, or treatment for cancer, within 3 years.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •Receipt of systemic glucocorticoids within 1 month prior to first dose of test article or any other cytotoxic or immunosuppressive drug within 6 months prior to first dose of test article. Receipt of any immunoglobulins and/or any blood products within 3 months of first test article administration or planned administration of any of these products during the study period.
- •Any significant disorder of coagulation or treatment with warfarin derivatives or heparin.
- •An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6 weeks of receipt of seasonal influenza vaccine.
- •Administration of an inactivated seasonal influenza vaccine within 14 days, or of a live, attenuated seasonal influenza vaccine within 30 days before the first test article dose, or of any other vaccine(s) not foreseen by the study protocol within 30 days before the first test article dose.
- •Planned administration of any vaccine(s) not foreseen by the study protocol through completion of the "Day 42" visit.
- •Any known or suspected allergy to any constituent of influenza vaccines or history of severe reaction to any previous influenza vaccination.
- •Known pregnancy, or a positive urine pregnancy test result prior to each test article dose.
- •Lactating or nursing.
- •Child in care.
结局指标
主要结局
Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain.
时间窗: At Day 42.
A seroprotected subject against the a/Indonesia/5/2005 (A/INDO) virus strain was defined as a subject with H5N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (\>=) the seroprotection cut-off of 1:40.
次要结局
- Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the H5N1 A/Indonesia and H5N1 A/Vietnam Virus Strains.(At Day 42)
- Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the H5N1 A/Indonesia Virus Strain.(At Day 385)
- Geometric Mean Increase (GMI) for Haemagglutination Inhibition (HI) Antibodies Against the H5N1 A/Indonesia Virus Strain.(At Day 385.)
- Number of Subjects Seroprotected as Regards Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain.(At Day 0 and Day 182)
- Number of Subjects Reporting Solicited Local Symptoms.(During the 7-day (Days U0-U6) post-vaccination periods post Doses 1 and 2 of vaccine/placebo, across doses (Year 2))
- Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain(At Day 42.)
- Number of Subjects of Less Than 6 Years of Age Reporting Solicited General Symptoms.(During the 7-day (Days U0-U6) post-vaccination periods post Doses 1 and 2 of vaccine/placebo, across doses (Year 2))
- Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain.(At Day 0 and Day 385)
- Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain.(At Day 0 and Day 385)
- Number of Subjects Seropositive for Microneutralization (MN) Antibodies Against the H5N1 A/Indonesia Virus Strain.(At Days 0 and 42)
- Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)(From Day U0 to Day U385)
- Number of Subjects With Normal and Abnormal Haematological Parameters Assessed With Respect to Haematocrit (Hcr) and Haemoglobin (Hgb)(From Day 0 up to Day 385)
- Microneutralization (MN) Antibody Titers Against the H5N1 A/Indonesia and H5N1 A/Vietnam Virus Strains.(At Days 0, 42, 182 and 385)
- Number of Subjects With Medically-attended Adverse Events (MAEs)(From Day U0 up to Day U385)
- Number of Subjects With Normal and Abnormal Haematological Parameters Assessed With Respect to Lymphocytes (LYM) and Monocytes (MON)(From Day 0 up to Day 385)
- Number of Subjects at Least 6 Years of Age Reporting Solicited General Symptoms.(During the 7-day (Days U0-U6) post-vaccination periods post Doses 1 and 2 of vaccine/placebo, across doses (Year 2))
- Number of Subjects Reporting Pregnancies, and Outcomes of These Reported Pregnancies(From Day U0 to Day U385)
- Number of Subjects With Normal and Abnormal Haematological Parameters Assessed With Respect to Basophils (BAS) and Eosinophils (EOS)(From Day 0 up to Day 385)
- Number of Subjects With Normal and Abnormal Haematological Parameters Assessed With Respect to Neutrophils (NEU) and Platelets (PLA)(From Day 0 up to Day 385)
- Number of Subjects Reporting Any Unsolicited Adverse Events (AEs).(During the 42-day (Days U0-U41) post-vaccination period following Dose 1 of Influenza A (H5N1) Virus monovalent vaccine)
- Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Alanine Aminotransferase (ALAT) and Aspartate Aminotransferase (ASAT)(From Day 0 up to Day 385)
- Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Total Bilirubin (T-BIL) and Bilirubin Conjugated/Direct (BIL-C/D)(From Day 0 up to Day 385)
- Number of Subjects With Normal and Abnormal Biochemical Parameters Assessed With Respect to Creatinine (CREA) and Blood Urea Nitrogen (BUN)(From Day 0 up to Day 385)
- Number of Subjects With Normal and Abnormal Haematological Parameters Assessed With Respect to Red and White Blood Cells (RBC and WBC)(From Day 0 up to Day 385)
- Number of Subjects Reporting Serious Adverse Events (SAEs)(From Day U0 up to Day U385)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
1 期
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years OldInfluenzaNCT01236040GlaxoSmithKline521
撤回
2 期
Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in AdultsInfluenzaNCT01008956GlaxoSmithKline
终止
2 期
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in ChildrenInfluenzaNCT01003418GlaxoSmithKline8
已完成
1 期
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In AdultsHealthyNCT01250795Fraunhofer, Center for Molecular Biotechnology100
已完成
2 期
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of AgeInfluenzaNCT01974895GlaxoSmithKline316